Merck

The Pistoia Alliance is announcing that it has successfully completed a proof of concept on the digital transfer via cloud of analytical High Performance Liquid Chromatography methods.

When considering an investment in a startup pharmaceutical company, investors have a lot to consider. This article explores some of the areas where investors should seek answers before putting money on the table.

Measuring the total mutations in the DNA of cancer cells from circulating tumor DNA found in the blood can predict how a non-small cell lung cancer patient will respond to immunotherapy.

In April 2022, Cancer Research UK unveiled Cancer Research Horizons, its new approach to driving innovation in the field. Technology Networks had the opportunity to speak with two members of Cancer Research Horizon’s executive leadership team to learn more about some of the cutting-edge experimental capabilities that will be used to interrogate cancer biology more thoroughly.

Researchers have captured the first three-dimensional images that reveal how drug compounds work to stop Plasmodium parasites from spreading in the blood.

In a new study published in Science, a team describes the use of electricity to develop an approach that may make it easier and cheaper to create key compounds used in pharmaceuticals and other natural products.

Dotmatics has been announced as the formal name and brand for the combined entities of Insightful Science and Dotmatics.

The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).

In recent years there has been growing interest in expanding the list of “druggable” targets to include RNA. Now a study published in Nature provides evidence that suggests RNA could be a viable target.

A clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.